Home › Trial NCT00042016
Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Chronic Phase Who Are Refractory to Imatinib Mesylate (Gleevec)
- Trial IDNCT00042016
- StatusCompleted
- PhasePhase 2
- Study typeInterventional
- SponsorAstex Pharmaceuticals, Inc.
- Enrollment40
- Start date2002-07
- ConditionsChronic Myelogenous Leukemia
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.